what are we doing?

      Our Approach

      Thanks to our expertise in Targeted Protein Degradation (TPD) we take a multi-faceted approach to eliminate disease-causing proteins. Our proprietary Optigrade™ platform enables the robust discovery of therapeutic compounds with good biopharmaceutical properties.

      To maximizes the probability of developing a successful degrader drug, Captor exploits different approached to protein degradation: molecular glues, bifunctional degraders, and Obterons®. To unlock the potential of UPS (Ubiquitin Proteasome System) Captor Therapeutics is developing a large platform of ubiquitin ligases and associated ligands (LiLisTM). This approach will enable us to adapt the degradation process to therapeutic indication. Together, these components form the Optigrade™ platform – a robust drug discovery engine.

       

      At Captor Therapeutics, we cover all aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade™ Targeted Protein Degradation (TPD) platform allows for the sustainable creation of new drugs.

      Our integrated approach combines competencies in medicinal chemistry, molecular modelling, protein sciences, biophysics, and pharmacology. 1,100 m2 of laboratory space equipped with state-of-the-art machinery allows for full control of the drug development process and its dynamics.

      Supported by over 44 million EUR from European grants and private investors, we are currently working on several projects aiming at:

      (1) the development of first-in-class therapeutics for oncological and autoimmune indications and

      (2) the evolution of our Optigrade™ platform to allow the creation of second and third generation degrader drugs with enhanced efficacy, selectivity and pharmaceutical properties.

      Pipeline

      Captor is developing first-in-class molecules to treat cancer and autoimmune diseases. Currently, our pipeline consists of five fully-owned, differentiated drug projects addressing high unmet medical needs. We are focusing on cancers with limited treatment options and poor survival rates. In chronic autoimmune diseases, we desire to improve the quality of patients' lives by providing breakthrough orally available medicines.

      Importantly, our broadly applicable Optigrade™ targeted protein degradation (TPD) platform can continuously create new degrader molecules against additional high value drug targets, which will allow Captor to constantly replenish its drug pipeline as the more advanced projects are licensed out or commercialised.  

      Today, biologics and small molecule inhibitors represent the main therapeutic modalities applied in cancer and autoimmunity. The totally different mode of action of Captor’s TPD drugs allows for overcoming the limits of existing medicines and for developing novel therapies against drug targets that have not been previously addressed with classical drugs.

      At Captor we are planning to commercialize our products by out-licensing drug candidates to large Pharma and Biotechnology partners. Our business model combines internal development and collaboration so that we can maintain ownership of internal pipeline projects until a strategically optimum time for collaboration, while at the same time leveraging our Optigrade™ platform by establishing target based collaborations with partners.

      Grant Projects

      Grant projects co-funded by the National

      Centre for Research and Development:

      • Elaboration of interaction assays suitable for screening of the chemical compounds used in a first-in-class drug development (POIR.04.01.02-00-0147/16-00).

        Project carried out within the Measure 4.1 "Research and development", Sub-measure 4.1.4  "Regional research agendas" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund

        Project is realized by Consortium comprising: Institute of Immunology and Experimental Therapy Polish Academy of Sciences in Wroclaw, Captor Therapeutics Inc

        Value of the project: 4 314 375.00 PLN
        European Union financing: 3 834 558.00 PLN

        Goal and expected results of the project: development of scalable and sensitive high-throughput fluorescence assay allowing for rapid detection of active PROTAC compounds which induce degradation of pathological proteins.

      • Development and implementation of an innovative platform for the identification drug-like compounds (POIR.04.01.04-00-0116/16-00).

        Project carried out within the Measure 4.1 "Research and development", Sub-measure 4.1.1  "Application projects" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund

        Project realized by Consortium comprising: The National Centre of Research and Development Ltd, Captor Therapeutics Inc

        Value of the project: 4 968 788.76 PLN
        European Union financing: 4 260 002.76 PLN

        Goal and expected results:  development of two-stage high-throughput screening assay for low molecular weight compounds which induce targeted protein degradation.

      • Development of first-in-class anti-inflammatory drugs specifically degrading disease modifying proteins (POIR.01.01.01-00-0747/16-00).

        Project carried out within the Measure 1.1 "R&D projects of enterprises", Sub-measure 1.1.1  "Industrial research and development work implemented by enterprises" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund

        Value of the project: 32 164 999.43 PLN
        European Union financing: 24 460 751.26 PLN
         
        Goal and expected results: Development low molecular weight compunds inhibiting receptor proteins by applying the bispecific inductor degradation (BID) technology which will be drug candidates for patients ailed with rheumathoid arthritis or inflammatory bowel disease.
      • Small molecules as therapeutic intervention in multiple severe malignancies (POIR.01.01.01-00-0956/17-00).

        Project carried out within the Measure 1.1 "R&D projects of enterprises", Sub-measure 1.1.1  "Industrial research and developmend work implemented by enterprises" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund   

        Value of project: 35 902 013.75 PLN
        European Union financing: 27 683 098.00 PLN

        Goal and expected results of the project: Development and testing in the first stage of clinical tests of low molecular weight chemical compounds which will be future drug candidates in tumor therapies of  non-small lung cancer and triple negative breast cancer.

      • Application of targeted protein degradation technology in the treatment of psoriasis and rheumatoid arthritis (POIR.01.02.00-00-0079/18).

        Project carried out within the Priority Axis I: Supporting R&D carried out by enterprises”, Measure 1.2 „Sectoral R&D programmes”, as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund

        Value of project: 37 130 943.75 PLN
        European Union financing: 29 558 070.00 PLN

        Goal and expected results of the project: Discovery and development novel, first in class oral drugs targeting key drivers of rheumatoid arthritis, psoriasis and ulcerative colitis.

      • Discovery and Development of First-in-Class of Small Molecule Degrader As a Drug Candidate For the Treatment of Colorectal Cancer (POIR.01.02.00-00-0073/18).

        Project carried out within the Priority Axis I: Supporting R&D carried out by enterprises”, Measure 1.2 „Sectoral R&D programmes”, as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund

        Value of project: 32 041 906.25 PLN
        European Union financing: 25 510 680.00 PLN

        Goal and expected results of the project: Development of first, oral targeted therapy focused on interruption of the main cause of colorectal cancer (CRC). The efficacy and bioavailability of the drug candidate will be tested in preclinical phase, followed by the Phase I clinical trials.

      • Development of targeted oncogenic transcription factor degradation technology in the treatment of hepatocellular carcinoma (POIR.01.01.01-00-0740/19).

        Project carried out within the Measure 1.1 "R&D projects of enterprises", Sub-measure 1.1.1  "Industrial research and development work implemented by enterprises" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund.

        Value of the project: 36 389 016.25 PLN
        European Union financing: 28 959 643.00 PLN

        Goal of project: Development of a drug candidate in the treatment of hepatocellular carcinoma that allows the elimination of cancer cells through induced degradation of oncogenic transcription factor. The efficacy and bioavailability of the drug candidate will be tested in preclinical phase, followed by the Phase I clinical trials.

      • Development of technological platform in the area of targeted protein degradation and its implementation on the pharmaceutical market (POIR.01.01.01-00-0931/19).

        Project carried out within the Measure 1.1 "R&D projects of enterprises", Sub-measure 1.1.1  "Industrial research and development work implemented by enterprises" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund.

        Value of the project: 10 135 628.75 PLN
        European Union financing: 7 759 469.50 PLN

        Goal and expected results of the project: Development and implementation of technological platform through generation of modular small molecules capable of inducing protein degradation upon recruitment of novel ubiquitin ligases.

      • Development of non-toxic ligase ligands and their application in the treatment of autoimmune diseases (POIR.01.01.01-00-0741/19).

        Project carried out within the Measure 1.1 "R&D projects of enterprises", Sub-measure 1.1.1  "Industrial research and development work implementet by enterprises" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund.

        Value of the project: 34 441 900.00  PLN
        European Union financing: 27 411 400.00 PLN

        Goal and expected results of the project: Development of a drug candidate in the treatment of autoimmune diseases through generation of non-toxic ligase ligands. The efficacy and bioavailability of the drug candidate will be tested in preclinical phase, followed by the Phase I clinical trials.

      Technology

      Despite technological advances, many common diseases remain inadequately treated. Various drug targets, such as transcription factors, scaffolding proteins, and proteins with multiple functions are inaccessible to classical drugs and to antibodies.

      Targeted Protein Degradation (TPD) technology offers a great advantage over classical inhibitors due to its ability to remove proteins. The binding of a degrader molecule to the pathological protein of interest does not require the presence of an active site, consequently, it can be applied to a much larger number of protein classes, far beyond enzymes and receptors. Medical benefits of TPD include the potential to:

      (1) treat currently untreatable diseases,

      (2) overcome cancer resistance to classical drugs,

      (3) provide more efficacious treatments, and

      (4) offer prolonged efficacy and less frequent dosing.

      In principle, by using rationally designed small molecule degraders, we hijack the natural cellular processes and redirect the degradation machinery to remove specific disease-causing proteins.